Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway

Relevance to cancer-related fatigue

Sangmi Kim, Brian J Miller, Michael E Stefanek, Andrew H Miller

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cancer-related fatigue (CRF) is a common complication of cancer and its treatment that can significantly impair quality of life. Although the specific mechanisms remain poorly understood, inflammation is now considered to be a distinct component of CRF in addition to effects of depression, anxiety, insomnia, and other factors. One key biological pathway that may link inflammation and CRF is indoleamine 2,3-dioxygenase (IDO). Induced by inflammatory stimuli, IDO catabolizes tryptophan to kynurenine (KYN), which is subsequently converted into neuroactive metabolites. Here we summarize current knowledge concerning the relevance of the IDO pathway to CRF, including activation of the IDO pathway in cancer patients and, as a consequence, accumulation of neurotoxic KYN metabolites and depletion of serotonin in the brain. Because IDO inhibitors are already being evaluated as therapeutic agents in cancer, the elucidation of the relationship between IDO activation and CRF in cancer patients may lead to novel diagnostic and clinical approaches to managing CRF and its debilitating consequences. Cancer 2015. © 2015 American Cancer Society.

Original languageEnglish (US)
JournalCancer
DOIs
StatePublished - Feb 27 2015

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Fatigue
Inflammation
Neoplasms
Kynurenine
Sleep Initiation and Maintenance Disorders
Tryptophan
Serotonin
Anxiety

Cite this

Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway : Relevance to cancer-related fatigue. / Kim, Sangmi; Miller, Brian J; Stefanek, Michael E; Miller, Andrew H.

In: Cancer, 27.02.2015.

Research output: Contribution to journalArticle

@article{acc606173b824391af40e4b6ef2caa06,
title = "Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue",
abstract = "Cancer-related fatigue (CRF) is a common complication of cancer and its treatment that can significantly impair quality of life. Although the specific mechanisms remain poorly understood, inflammation is now considered to be a distinct component of CRF in addition to effects of depression, anxiety, insomnia, and other factors. One key biological pathway that may link inflammation and CRF is indoleamine 2,3-dioxygenase (IDO). Induced by inflammatory stimuli, IDO catabolizes tryptophan to kynurenine (KYN), which is subsequently converted into neuroactive metabolites. Here we summarize current knowledge concerning the relevance of the IDO pathway to CRF, including activation of the IDO pathway in cancer patients and, as a consequence, accumulation of neurotoxic KYN metabolites and depletion of serotonin in the brain. Because IDO inhibitors are already being evaluated as therapeutic agents in cancer, the elucidation of the relationship between IDO activation and CRF in cancer patients may lead to novel diagnostic and clinical approaches to managing CRF and its debilitating consequences. Cancer 2015. {\circledC} 2015 American Cancer Society.",
author = "Sangmi Kim and Miller, {Brian J} and Stefanek, {Michael E} and Miller, {Andrew H}",
note = "{\circledC} 2015 American Cancer Society.",
year = "2015",
month = "2",
day = "27",
doi = "10.1002/cncr.29302",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway

T2 - Relevance to cancer-related fatigue

AU - Kim, Sangmi

AU - Miller, Brian J

AU - Stefanek, Michael E

AU - Miller, Andrew H

N1 - © 2015 American Cancer Society.

PY - 2015/2/27

Y1 - 2015/2/27

N2 - Cancer-related fatigue (CRF) is a common complication of cancer and its treatment that can significantly impair quality of life. Although the specific mechanisms remain poorly understood, inflammation is now considered to be a distinct component of CRF in addition to effects of depression, anxiety, insomnia, and other factors. One key biological pathway that may link inflammation and CRF is indoleamine 2,3-dioxygenase (IDO). Induced by inflammatory stimuli, IDO catabolizes tryptophan to kynurenine (KYN), which is subsequently converted into neuroactive metabolites. Here we summarize current knowledge concerning the relevance of the IDO pathway to CRF, including activation of the IDO pathway in cancer patients and, as a consequence, accumulation of neurotoxic KYN metabolites and depletion of serotonin in the brain. Because IDO inhibitors are already being evaluated as therapeutic agents in cancer, the elucidation of the relationship between IDO activation and CRF in cancer patients may lead to novel diagnostic and clinical approaches to managing CRF and its debilitating consequences. Cancer 2015. © 2015 American Cancer Society.

AB - Cancer-related fatigue (CRF) is a common complication of cancer and its treatment that can significantly impair quality of life. Although the specific mechanisms remain poorly understood, inflammation is now considered to be a distinct component of CRF in addition to effects of depression, anxiety, insomnia, and other factors. One key biological pathway that may link inflammation and CRF is indoleamine 2,3-dioxygenase (IDO). Induced by inflammatory stimuli, IDO catabolizes tryptophan to kynurenine (KYN), which is subsequently converted into neuroactive metabolites. Here we summarize current knowledge concerning the relevance of the IDO pathway to CRF, including activation of the IDO pathway in cancer patients and, as a consequence, accumulation of neurotoxic KYN metabolites and depletion of serotonin in the brain. Because IDO inhibitors are already being evaluated as therapeutic agents in cancer, the elucidation of the relationship between IDO activation and CRF in cancer patients may lead to novel diagnostic and clinical approaches to managing CRF and its debilitating consequences. Cancer 2015. © 2015 American Cancer Society.

U2 - 10.1002/cncr.29302

DO - 10.1002/cncr.29302

M3 - Article

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -